# OnCo record nct03358472 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03358472/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03358472", "NCT03358472" ;
  schema:name "Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)"@en ;
  schema:description "A phase 3 trial of Pembrolizumab, Epacadostat, Cetuximab, Cisplatin and Carboplatin in Head and neck squamous cell carcinoma, run by Incyte Corporation, completed."@en ;
  schema:url <https://onco.cc/trials/nct03358472/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03358472> ;
  onco:status "completed" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/epacadostat/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/incyte/> .